Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

Key facts

Sponsor

BioWest Therapeutics Inc

Principal Investigator

Jim Pankovich

BioWest Therapeutics Inc

Intervention

MBI 226 Acne Solutions(drug)

Enrollment

255 enrolled

Eligibility

12 years · All sexes

Timeline

2003 – 2003

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anterior cutaneous nerve entrapment syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07544251
  Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
  Integrative Skin Science and Research
• RECRUITINGNANCT07406893
  Reduction of Bacterial Seeding in Total Shoulder Arthroplasty
  St. Louis University
• ACTIVE NOT RECRUITINGNCT07205107
  Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
  Bausch Health Americas, Inc.
• RECRUITINGNANCT07056673
  Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study
  Shenyang Medical College
• RECRUITINGPHASE3NCT06447480
  Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients
  Centre Hospitalier Universitaire de Nice
• RECRUITINGNCT06850389
  PMCF Investigation of Medical Device ChitoCare® Medical
  Primex ehf
• RECRUITINGPHASE1NCT06989840
  Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
  Sagimet Biosciences Inc.
• RECRUITINGNCT07085247
  The Role of Cutibacterium Acnes in the Development of Degenerative Lumbar Intervertebral Disc Disease
  Masaryk University

See all trials for Anterior cutaneous nerve entrapment syndrome →